Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ontario Clinical Oncology Group (OCOG)
With
Cancer Care Ontario
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women (or men) with histological evidence of breast cancer for whom potentially curative treatment is planned.
Based on clinical information (physical exam, imaging):
1. Stage III breast cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4), or
You may not be if
Considered for combined modality therapy (surgical resection, chemotherapy, radiotherapy) of curative intent.
Age \< 18 years,
ECOG performance status \> and = 3,
Prior systemic therapy (e.g. neo-adjuvant chemotherapy or hormonal therapy) for current breast cancer,
Previous staging investigations for current breast cancer,
Breast cancer with primary histological subtypes other than ductal or lobular (Note: Patients with mixed disease will be eligible for randomization),
Clinical suspicion of metastatic disease,
Relative contraindications to PET (e.g. uncontrolled diabetes (i.e. inability to decrease serum glucose below 10.2 mmol/L), claustrophobia, inability to be still for 30 minutes),
Inability to lie supine for imaging with PET-CT,
Inability to undergo CT because of known allergy to contrast,
History of another invasive malignancy within the previous two years (exception of non melanoma skin cancer) or a synchronous primary cancer, including a synchronous contralateral breast cancer (Note: Patients found to have a contralateral breast cancer on study imaging following randomization will remain in the study),
Known pregnancy or lactating female,
Inability to complete the study or required follow-up.
Clareo Health | Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
